مقالات پذیرفته شده در نهمین کنگره بین المللی زیست پزشکی
Urinary NT-proBNP as a Non-Invasive Diagnostic Biomarker in Alcohol-Induced Coronary Heart Failure: Influence of Respiratory Infections and Acid-Blocker Therapy
Urinary NT-proBNP as a Non-Invasive Diagnostic Biomarker in Alcohol-Induced Coronary Heart Failure: Influence of Respiratory Infections and Acid-Blocker Therapy
Introduction: Alcohol-induced cardiomyopathy is an under-recognized contributor to coronary heart failure (CHF), particularly in clinical settings where invasive diagnostics are impractical. NT-proBNP is a well-established serum biomarker for heart failure, but its urinary excretion profile—especially in alcohol-related CHF—remains insufficiently studied. Inflammatory states such as respiratory infections may further elevate NT-proBNP levels, while acid-blocker medications, commonly used among alcohol-consuming populations, could influence both cardiac and renal biomarker dynamics. Clarifying these interactions is crucial for advancing non-invasive and scalable diagnostic strategies. This study therefore aims to evaluate urinary NT-proBNP as a non-invasive biomarker for alcohol-induced CHF and to investigate how respiratory infections and acid-blocker therapy modify its diagnostic performance.
Methods: A cross-sectional observational study will be conducted involving 100 adult patients with a history of chronic alcohol use and a clinical diagnosis of coronary heart failure. Patients will be stratified according to the presence of respiratory infection and ongoing acid-blocker therapy. Paired urinary and serum NT-proBNP levels will be quantified using ELISA. Additional clinical parameters—including echocardiography findings, inflammatory markers, and renal function—will also be recorded. Multivariate regression analysis will be used to determine the independent effects of respiratory infections and acid-blocker therapy on NT-proBNP levels, adjusting for confounders such as age, sex, and kidney function.
Results: It is expected that urinary NT-proBNP will show a strong correlation with alcohol-induced CHF severity, thereby demonstrating potential as a reliable, low-cost, and non-invasive diagnostic biomarker. Furthermore, respiratory infections are anticipated to increase NT-proBNP levels due to heightened cardiac stress, while acid-blocker therapy may attenuate these levels. These findings are expected to uncover clinically relevant interactions influencing biomarker interpretation.
Conclusion: The validation of urinary NT-proBNP as a diagnostic biomarker could enable earlier and less invasive detection of alcohol-induced CHF, particularly in healthcare settings with limited access to echocardiography or venipuncture. By accounting for modifying factors such as respiratory infections and acid-blocker use, this research may improve patient risk stratification, monitoring, and treatment planning, ultimately contributing to more precise and accessible heart failure care.